Johnson & Johnson’s JNJ -0.33% Covid-19 vaccine could be back in circulation this weekend—albeit with possible restrictions—depending on a recommendation Friday by a federal advisory panel.

J&J vaccine injections were put on hold last week after reports of rare blood-clot conditions in a handful of recipients, including one fatality.

Many public-health authorities, however, contend that the benefits of the vaccine outweigh the risks. Anthony Fauci, President Biden’s chief medical adviser, has predicted the U.S. pause would end as soon as Friday, perhaps with new restrictions or warnings.

The Advisory Committee on Immunization Practices, which includes doctors and public-health officials, is expected to advise the Food and Drug Administration and Centers for Disease Control and Prevention to either continue or lift the pause after a meeting Friday.

A recommendation to lift the pause—and agreement by the FDA and CDC—could put the vaccine back in circulation as early as this weekend, because millions of doses have already been distributed to vaccine sites.

The lifting of the pause could be accompanied by restrictions limiting the vaccine’s use to older adults, as well as possible warnings about the potential clot risk, according to people familiar with the matter.

The ACIP meeting is scheduled to begin at 11 a.m. Eastern time, with a potential vote by 5 p.m.

It will be the ACIP’s second emergency meeting in 10 days to discuss the J&J vaccine. The committee, which advises the CDC, met April 14, one day after use of J&J’s vaccine was paused. But the committee, meeting online, deferred voting on a recommendation because members wanted more information about the vaccine’s risks and benefits.